Supplementary Materials

Supplementary Material for:

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Marco L. Davila, Isabelle Riviere, Xiuyan Wang, Shirley Bartido, Jae Park, Kevin Curran, Stephen S. Chung, Jolanta Stefanski, Oriana Borquez-Ojeda, Malgorzata Olszewska, Jinrong Qu, Teresa Wasielewska, Qing He, Mitsu Fink, Himaly Shinglot, Maher Youssif, Mark Satter, Yongzeng Wang, James Hosey, Hilda Quintanilla, Elizabeth Halton, Yvette Bernal, Diana C. G. Bouhassira, Maria E. Arcila, Mithat Gonen, Gail J. Roboz, Peter Maslak, Dan Douer, Mark G. Frattini, Sergio Giralt, Michel Sadelain,* Renier Brentjens*

*Corresponding author. E-mail: brentjer@mskcc.org (R.B.); m-sadelain@ski.mskcc.org (M.S.)

Published 19 February 2014, Sci. Transl. Med.6, 224ra25 (2014)
DOI: 10.1126/scitranslmed.3008226

This PDF file includes:

  • Fig. S1. Trial scheme.
  • Fig. S2. CRP levels in patients with sCRS.
  • Fig. S3. ROC curve for CRP.
  • Fig. S4. Management scheme for patients treated with CAR T cells.
  • Table S1. Apheresis and T cell production characteristics.
  • Table S2. Detection of B cells and CAR T cells in the BM by deep sequencing.
  • Table S3. Absolute maximum cytokine values after CAR T cell infusion.
  • Table S4. Adverse events.
  • Table S5. CAR T cells in the CSF of patients with neurologic changes.

[Download PDF]